lauryl mandelate | 66267-58-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: lauryl mandelate
• 英文别名: dodecyl 2-hydroxy-2-phenylacetate
• CAS: 66267-58-1
• 化学式: C₂₀H₃₂O₃
• 分子量: 320.472
• InChiKey: MHCRUEWWUQBSGV-UHFFFAOYSA-N

物化性质

• 沸点：
  430.1±25.0 °C(Predicted)
• 密度：
  0.995±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  23
• 可旋转键数：
  14
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  十二烷醇 、 扁桃酸乙酯 在 silica gel 作用下， 以95%的产率得到lauryl mandelate
  参考文献：
  名称：

  Synthesis of fatty alcohol esters of alpha-hydroxy carboxylic acids and their use as percutaneous absorption enhancers

  摘要：

  本发明提供了一种新颖的方法，用于制备α-羟基羧酸的脂肪醇酯。在本发明的一种形式中，通过将α-羟基羧酸的较低烷基酯转化为脂肪醇酯，从而通过醇解（即酯交换）生产目标脂肪醇酯的α-羟基羧酸。酯交换过程是一个平衡反应，可以通过化学催化（即酸或碱）或酶催化来推动朝着所需产物的方向进行。将反应朝着所需产物的方向推动的一种首选方法是通过降低其中一个产物的浓度（例如，一旦形成较低沸点的醇，就进行蒸馏）。将反应朝着所需产物的方向推动的另一种首选方法是通过增加其中一个反应物的浓度（例如，添加更多的起始酯）。

  公开号：

  US20060084154A1

文献信息

• Novel SO3H-functionalized polyoxometalate-based ionic liquids as highly efficient catalysts for esterification reaction
  作者：Mosadegh Keshavarz、Nasir Iravani、Abolfath Parhami

  DOI：10.1016/j.molstruc.2019.04.027

  日期：2019.8

  Abstract Three novel heteropolyanion-based Bronsted acidic ionic liquids (BAILs), butane mono sulfoacid-functionalized 1,10-phenanthrolinum, butane mono and bis sulfoacid-functionalized 1,4-dimethylpiperazinium salts of phosphortungstate catalyst (PhBs1-PW, [PipBs1]3-PW and [PipBs2]3-(PW)2) were synthesized and well characterized with FTIR, 1H and 13C NMR, Electro-Spray Ionization Mass Spectrometry

  摘要 三种新型杂多阴离子型布朗斯台德酸性离子液体 (BAILs)、丁烷单磺酸官能化 1,10-菲啉、丁烷单和双磺酸官能化 1,4-二甲基哌嗪鎓盐的磷钨酸盐催化剂 (PhBs1-PW, [PipBs1]3 -PW 和 [PipBs2]3-(PW)2) 被合成并用 FTIR、1H 和 13C NMR、电喷雾电离质谱 (ESI-MS)、元素分析 (CHNS)、EDX 和 TG 分析技术进行了很好的表征。使用这些催化剂进行一元羧酸与一元醇的酯化反应。引入的催化剂在反应后表现出自分离性能，经六次循环试验证实，该催化剂易于回收且可稳定重复使用。此外，双磺酸官能化的 1，
• Synthesis of fatty alcohol esters of alpha-hydroxy carboxylic acids, the use of the same as percutaneous permeation enhancers, and topical gels for the transdermal delivery of steroids
  申请人：Jones S. Gerald

  公开号：US20070082039A1

  公开（公告）日：2007-04-12

  The present invention provides a novel approach for the preparation of fatty alcohol esters of α-hydroxy carboxylic acids. The present invention also provides a novel topical gel for the transdermal delivery of steroids using the fatty alcohol esters as permeation enhancers.

  本发明提供了一种制备α-羟基羧酸脂肪醇酯的新方法。本发明还提供了一种新型的局部凝胶，使用脂肪醇酯作为渗透增强剂，用于经皮输送类固醇。
• SYNTHESIS OF FATTY ALCOHOL ESTERS OF ALPHA-HYDROXY CARBOXYLIC ACIDS AND THEIR USE AS PERCUTANEOUS ABSORPTION ENHANCERS
  申请人：Jones, JR. Gerald S.

  公开号：US20120289725A1

  公开（公告）日：2012-11-15

  The present invention provides a novel approach for the preparation of fatty alcohol esters of α-hydroxy carboxylic acids. In one form of the invention, the target fatty alcohol ester of α-hydroxy carboxylic acid is produced by converting a lower alkyl ester of α-hydroxy carboxylic acid into a fatty alcohol ester of α-hydroxy carboxylic acid via alcoholysis (i.e., transesterification). The transesterification process is an equilibrium reaction, catalyzed chemically (i.e., with acids or bases) or enzymatically, that is shifted in the desired direction to produce the desired product. One way of shifting the reaction in the direction of the desired product is by reducing the concentration of one of the products (e.g., distillation of a lower-boiling alcohol as it is formed). Another preferred way of shifting the reaction in the direction of the desired product is by increasing the concentration of one of the reactants.

  本发明提供了一种制备α-羟基羧酸脂肪醇酯的新方法。在发明的一种形式中，目标α-羟基羧酸脂肪醇酯是通过将α-羟基羧酸的低碳酸酯转化为脂肪醇酯的方式制备的，该转酯化过程是一个平衡反应，可以通过化学催化剂（如酸或碱）或酶催化剂进行催化，以产生所需的产物。将反应向所需产物方向转移的一种方式是通过降低其中一种产物的浓度（例如，随着低沸点醇的形成进行蒸馏）。另一种首选的将反应向所需产物方向转移的方式是通过增加其中一种反应物的浓度。
• SYNTHESIS OF FATTY ALCOHOL ESTERS OF ALPHA-HYDROXY CARBOXYLIC ACIDS AND THEIR USE AS PERCUTANEOUS ABSORPTION ENHANCERS
  申请人：Chemic Laboratories, Inc

  公开号：EP1802763A2

  公开（公告）日：2007-07-04
• NOVEL ESTER CONTAINING COMPOSITIONS AND METHODS
  申请人：St. Laurent Joseph P.

  公开号：US20130089577A1

  公开（公告）日：2013-04-11

  Described herein are compositions (e.g., a pharmaceutical composition) and methods for controlling the delivery of a therapeutic agent, and their use in the treatment and/or prevention of diseases and disorders.